Thrombocytopenia
Conditions
Brief summary
The overall design of this clinical study is a single center, randomized, open label, single dose, two sequence, two cycle bioequivalence trial in healthy individuals under fasting conditions. According to the randomized crossover self-control method, healthy volunteer subjects were orally administered with Eltrombopag Olamine Tablets produced by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Reference Listed Drug (RLD) on an empty stomach to evaluate the human bioequivalence of single dose administration, providing reference for their clinical evaluation and medication.
Interventions
Eltrombopag Tablets is a small molecule non peptide thrombopoietin receptor agonist.
Eltrombopag Tablets is a small molecule non peptide thrombopoietin receptor agonist.
Sponsors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Sign the informed consent before the trial, and fully understand the trial content, process and possible adverse reactions; * Able to complete the study according to the requirements of the trial protocol; * The participants (including their partners) are willing to voluntarily use effective contraceptive methods within 6 months from screening until the last dose of study drug, as detailed in the Appendix; * Male and female subjects aged 18-55 years old (including 18 and 55 years old); * he body weight of male subjects should not be less than 50 kg and the body weight of female subjects should not be less than 45 kg. Body mass index (BMI) = weight (kg)/height 2 (m2), BMI in the range of 18-28 kg/m2 (including the cut-off value); * Health condition: History of no heart, liver, kidney, digestive tract, nervous system, mental disorders, metabolic disorders, etc； * The physical examination was normal or abnormal without clinical significance.
Exclusion criteria
* Smoking more than 5 cigarettes per day in the 3 months before the study; * Allergic constitution (multi-drug and food allergy); * A history of drug and/or alcohol abuse (drinking 14 units of alcohol per week: 1 unit = 285 mL beer, or 25 mL spirits, or 100 ml wine); * Donation or massive blood loss (\> 400 mL) within 3 months before screening; * Taking any drugs that alter liver enzyme activity 28 days before screening; * Have taken any prescription medication, over-the-counter medication, any vitamin product or herbal medicine within 14 days before screening; * Those who had taken special diet (including dragon fruit, mango, grapefruit, etc.) or had strenuous exercise within 2 weeks before screening, or had other factors affecting drug absorption, distribution, metabolism, and excretion; * Combined with the following inhibitors or inducers of CYP3A4, P-gp, or Bcrp, such as itraconazole, ketoconazole, or dronedarone; * A recent major change in diet or exercise habits; * Have taken a study drug or participated in a clinical trial of the drug within three months before taking the study drug; * A history of dysphagia or any gastrointestinal disorder affecting drug absorption or a history of cholecystectomy or biliary tract disease; * Have any condition that increases the risk of bleeding, such as hemorrhoids, acute gastritis or gastric and duodenal ulcers; * ECG abnormalities have clinical significance; * The female subjects were lactating or seropositive for pregnancy during the screening or test period; * Clinically significant abnormalities on clinical examination or other clinical findings (including but not limited to gastrointestinal, renal, hepatic, neurological, hematologic, endocrine, oncologic, pulmonary, immune, psychiatric, or cardio-cerebrovascular diseases); * Viral hepatitis (including hepatitis B and C), AIDS antibody, treponema pallidum antibody positive; * From the screening stage to the onset of acute illness before study medication; * Consumption of chocolate, any caffeinated or xanthine-rich food or beverage 48 hours before taking the study drug; * Have taken any alcohol-based product within 24 hours before taking the study medication; * Individuals who test positive for alcohol and drugs or have a history of drug abuse within the past five years or have used drugs in the three months prior to the experiment; * Difficulty in blood collection or inability to tolerate venipuncture blood collection; * The subject is unable or unable to comply with ward management regulations; * The subject is unable to complete the experiment due to personal reasons; * Other researchers determine that it is not suitable for selection in this project.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Relative bioavailability (F) | Before administration and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 12, 24, 48, 72 hours after administration | Relative bioavailability |
| Maximum Concentration (Cmax) | Before administration and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 12, 24, 48, 72 hours after administration | Maximum Concentration |
| Time to maximum concentration (Tmax) | Before administration and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 12, 24, 48, 72 hours after administration | Time to maximum concentration following drug administration. |
| Area under the drug-time curve (AUC) | Before administration and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 12, 24, 48, 72 hours after administration | Area under the drug-time curve |
| Apparent terminal elimination half-life (t1/2) | Before administration and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 12, 24, 48, 72 hours after administration | Apparent terminal elimination half-life following drug administration. |
| Apparent volume of distribution (Vd/F) | Before administration and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 12, 24, 48, 72 hours after administration | Apparent volume of distribution |
| Clearance rate (CL/F) | Before administration and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 12, 24, 48, 72 hours after administration | Clearance rate |
| Apparent terminal elimination rate constant (λz) | Before administration and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 12, 24, 48, 72 hours after administration | Apparent terminal elimination rate constant. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of adverse events | From the first dose to the end of follow-up | Occurrence of all adverse events (AEs), serious adverse events (SAEs), and treatment-related adverse events (TEAEs) were recorded. |
Countries
China
Outcome results
None listed